Paradigm Biocapital Advisors’s Terns Pharmaceuticals TERN Stock Holding History

Paradigm Biocapital Advisors’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,216,499	Closed	-$117M	–	37
2026 Q1	$117M	Buy	2,216,499 +1,406,213	+174%	+$57.8M	2.39%	13
2025 Q4	$32.7M	Buy	+810,286	New	+$18.7M	0.84%	24

Other funds holding TERN

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Paradigm Biocapital Advisors's TERN Position: Q2 2026 in Review

Paradigm Biocapital Advisors sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 2,216,499 shares — an estimated $117M sold.

Paradigm Biocapital Advisors first reported a position in TERN in Q4 2025 and held it in 2 quarters. The position peaked at $117M in Q1 2026. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.

Paradigm Biocapital Advisors reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Paradigm Biocapital Advisors sold 2,216,499 Terns Pharmaceuticals shares in Q2 2026, an estimated $117M.
Paradigm Biocapital Advisors first reported a position in Terns Pharmaceuticals in Q4 2025 and held it in 2 quarters.
Paradigm Biocapital Advisors's Terns Pharmaceuticals position peaked at $117M in Q1 2026.
1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.

Based on Paradigm Biocapital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.